EUVIMEDEUVIMED entdecken
Crossref

Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis

Rochelle Liverman, Anastacia Serluco, Gwen Nance, Roshan George iD, Dellys Soler Rodriguez, Shriprasad Deshpande iD, Chad Mao iD, Rouba Garro, Inci Yildirim iD

Pediatric Transplantation · 2023

DOI: 10.1111/petr.14493 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Transplantation, 2023. Verfasst von Rochelle Liverman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Children's Healthcare of Atlanta, Georgia, Atlanta, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Heart Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytomegalovirus (CMV) is associated with morbidity and mortality in solid organ transplant recipients (SOTR). Valganciclovir (VGC) is extensively used for prophylaxis. Optimal dosing in children, risk factors for failure, and the impact of dose adjustments on CMV DNAemia is not well established.

Methods

This retrospective cohort study of pediatric SOTR transplanted between 2010–2018 evaluated the epidemiology of CMV DNAemia and used Cox‐regression to assess the risk factors for CMV DNAemia within one‐year following SOTR.

Results

In 393 pediatric SOTR (heart [96, 24.4%], kidney [180, 45.6%], liver [117, 29.8%]; median age 9.5 ± 0.3 years), overall CMV DNAemia incidence was 6.6/10 000 days (95%CI 5.1/10 000–7.9/10 000) and varied by organ groups: heart 8.2/10 000 days (95%CI 4.9/10 000–11.4/10 000), kidney 5.8/10 000 days (95%CI 3.9/10 000–7.8/10 000), liver 6.2/10 000 days (95%CI 3.7/10 000–8.7/10 000). CMV DNAemia was detected in 75 of 275 (27.2%) patients who received prophylaxis (40 cases occurred during prophylaxis and 35 occurred after completion of prophylaxis). The median VGC dose given according to institutional weight‐based algorithm was approximately 1.5‐fold lower than the manufacturer‐recommended dose. This discordance was more prominent at younger age groups (3.2‐fold lower in

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsHeart TransplantationHumansChildChild, PreschoolValganciclovirCytomegalovirusAntiviral AgentsIncidenceRetrospective StudiesRisk FactorsTransplant RecipientsKidneyLiverGanciclovir

Stichwörter der Autor:innen

cytomegaloviruspediatricssolid organ transplantvalganciclovir

Substanzen

ValganciclovirAntiviral AgentsGanciclovir

Autor:innen und Institutionen

  • Children's Healthcare of Atlanta, Georgia, Atlanta, USA.
  • Joe DiMaggio Children's Hospital, Florida, Hollywood, USA.
  • Division of Pediatric Nephrology, Emory University School of Medicine, Georgia, Atlanta, USA.
  • Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Emory University School of Medicine, Georgia, Atlanta, USA.
  • Division of Pediatric Cardiology, Children's National Hospital, DC, Washington, USA.
  • Division of Pediatric Cardiology, Emory University School of Medicine, Georgia, Atlanta, USA.

ORCID-Profile: Roshan George, Shriprasad Deshpande, Chad Mao, Inci Yildirim

Zitieren

APA

Liverman, R., Serluco, A., Nance, G., George, R., Rodriguez, D. S., Deshpande, S., Mao, C., Garro, R., & Yildirim, I. (2023). Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis. Pediatric Transplantation. https://doi.org/10.1111/petr.14493

Vancouver

Liverman R, Serluco A, Nance G, George R, Rodriguez DS, Deshpande S, et al. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis. Pediatric Transplantation. 2023. doi:10.1111/petr.14493

BibTeX
@article{Liverman2023,
  author = {Liverman, Rochelle and Serluco, Anastacia and Nance, Gwen and George, Roshan and Rodriguez, Dellys Soler and Deshpande, Shriprasad and Mao, Chad and Garro, Rouba and Yildirim, Inci},
  title = {Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis},
  journal = {Pediatric Transplantation},
  year = {2023},
  doi = {10.1111/petr.14493}
}
Kostenlos starten →